Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Nichola Cooper, A.J. Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F Ypma, Vickie McDonald, Charles Percy, Milan Košťál, Isaac Goncalves, Lachezar H. Bogdanov, Terry B Gernsheimer, Remco Diab, Mengjie Yao, Ahmed Daak, David J Kuter

Blood (2023) 142 (Supplement 1): 685.

https://doi.org/10.1182/blood-2023-177808

Published: 2023

Journal Articles

Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag

Waleed Ghanima, Vickie McDonald, Milica Putnik, Brian Jamieson, Stefan Rune Lethagen

Blood (2023) 142 (Supplement 1): 1226.

https://doi.org/10.1182/blood-2023-190106

Published: 2023

Journal Articles

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J Kuter, Hanny Al-Samkari, James B. Bussel, Anna Hultberg, Filip Matthijssens, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian Newland

Blood (2023) 142 (Supplement 1): 689.

https://doi.org/10.1182/blood-2023-189125

Published: 2023

Journal Articles

Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience

Bruno Fattizzo, Marta Bortolotti, Norma N. Fantini, Andreas Glenthøj, Marc Michel, Mariasanta Napolitano, Simona Raso, Frederick Chen, Vickie McDonald, Irina Murakhovskaya, Josephine Mathilde Iris Vos, Andrea Patriarca, Maria Eva Mingot-Castellano, Giulio Giordano, Margherita Scarrone, Tomás José González-López, Laura Trespidi, Daniele Prati, Wilma Barcellini

Blood (2023) 141 (16): 2016–2021.

https://doi.org/10.1182/blood.2022018890

Published: 2023

Includes: Supplemental data

Journal Articles

Comparative Effectiveness of Fostamatinib Vs. Rituximab in Refractory Chronic Immune Thrombocytopenia: A Network Meta-Analysis

Andrew Laws, David Gomez-Ulloa, Eva Calvo, Duncan Stacey, Jean Hamilton, Vickie McDonald

Blood (2022) 140 (Supplement 1): 2687–2688.

https://doi.org/10.1182/blood-2022-157734

Published: 2022

Journal Articles

Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

Vickie McDonald, Charlotte Bradbury, Kate Talks, Gillian Lowe, Sue Pavord, Gillian Evans, Manoharan Andiappan, Darcie Sandschafer, Vitor Jose De Sousa Barbosa, Lorraine Stephens, Nichola Cooper

Blood (2022) 140 (Supplement 1): 2678–2680.

https://doi.org/10.1182/blood-2022-157698

Published: 2022

Journal Articles

Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience

Marta Bortolotti, Norma Fantini, Andreas Glenthøj, Marc Michel, Mariasanta Napolitano, Simona Raso, Frederick Chen, Vickie McDonald, Irina Murakhovskaya, Josephine M.I. Vos, Andrea Patriarca, Maria Eva Mingot, Giulio Giordano, Margherita Scarrone, Laura Trespidi, Daniele Prati, Wilma Barcellini, Bruno Fattizzo

Blood (2022) 140 (Supplement 1): 2440–2442.

https://doi.org/10.1182/blood-2022-156656

Published: 2022

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al-Samkari, James B. Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland

Blood (2022) 140 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2022-167838

Published: 2022

Journal Articles

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Blood (2021) 138 (Supplement 1): 14.

https://doi.org/10.1182/blood-2021-145128

Published: 2021

Journal Articles

Rationale and Design of an Observational Multicenter Study to Evaluate the Use and Effectiveness of Avatrombopag in Adult Patients with Immune Thrombocytopenia: The Adopt Study

Vickie McDonald, Axel Matzdorff, Åsa Mellbring, Jameel Nazir, Daniel Lindqvist, Elena Santagostino

Blood (2021) 138 (Supplement 1): 4210.

https://doi.org/10.1182/blood-2021-144690

Published: 2021

Journal Articles

How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry

Vickie McDonald, Gerorge Loughlin, Andrew Laws, Duncan Stacey, Jeffrey Spears, Atiqa Miah, Haroon Miah, Quentin Hill, Nichola Cooper, Michael Makris, Charlotte Bradbury, Adrian C. Newland

Blood (2021) 138 (Supplement 1): 1016.

https://doi.org/10.1182/blood-2021-152650

Published: 2021

Journal Articles

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Waleed Ghanima, Vickie McDonald, Shivi Jain, Monica Carpenedo, Esther N. Oliva, Anna Hultberg, Domenica Gandini, Erik Hofman, Tonke Van Bragt, Wim Parys, Benjamin van Hoorick, Yoshitaka Miyakawa, Catherine M. Broome

Blood (2021) 138 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2021-153261

Published: 2021

Journal Articles

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

David J. Kuter, MD, Merlin Efraim, MD, Jiri Mayer, MD, Vickie McDonald, MD, Robert J. Bird, FRACP,FRCP,FRCPA,MBBS,MRCP, Thomas Regenbogen, MD, Mamta Garg, MD FRCP, FRCPath, Zane Kaplan, MBBS(Hons) BMedSc(Hons) PhDFRACP FRCPA, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-134932

Published: 2020

Journal Articles

Evans' Syndrome in Adults: An Observational Multicentre Study

Bruno Fattizzo, MD, Marc Michel, Juri Alessandro Giannotta, MD, Dennis Lund Hansen, Montserrat Lopez Rubio, PhD, Emanuele Sutto, MD, Nicola Bianchetti, MD, Andrea Patriarca, MD, Silvia Cantoni, Maria Eva Mingot-Castellano, PhD MD, Vickie McDonald, MD, Marco Capecchi, MD, Josephine M.I Vos, Paola Bianchi, BSc, PhD, Nicola Vianelli, MD, Frederick Chen, MD, Henrik Frederiksen, MD PhD Prof, Tomas Jose Gonzalez-Lopez, Wilma Barcellini

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136900

Published: 2020

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Adrian C. Newland, Howard A. Liebman, MD, Vickie McDonald, MD, Marc Michel, Yoshitaka Miyakawa, Wim Parys, MD, Hans De Haard, Peter Ulrichts, Marie Godar, Kristof De Beuf, Jaume Ayguasanosa, Catherine M Broome, David J. Kuter, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141161

Published: 2020

Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 87.

https://doi.org/10.1182/blood-2019-122336

Published: 2019

Journal Articles

Outcomes Following Placement of Venous Stents for Treatment of Thrombotic Venous Disease

Karen Breen, MD, Prakash Saha, Narayan Karanunithy, Beverley Hunt, Alexander Cohen, Vickie McDonald, James Uprichard, Michael Fay, MBBCHBAO, FRCPath, Stephen Black

Blood (2017) 130 (Supplement 1): 697.

https://doi.org/10.1182/blood.V130.Suppl_1.697.697

Published: 2017

Journal Articles

Characterizing the United Kingdom Congenital Thrombotic Thrombocytopenic Purpura Population

Ferras Alwan, MBBS, Chiara Vendramin, Ri Liesner, Tina Dutt, Amanda Clark, Jayashree Motwani, Will Lester, Vickie McDonald, Rachel Rayment, Nichola Cooper, MA, MD MRCP, FRCPath, Richard Gooding, Hamish Lyall, Tina Biss, MD, Joost van Veen, Henry G Watson, John-Paul Westwood, Mari Thomas, Marie Scully

Blood (2017) 130 (Supplement 1): 3616.

https://doi.org/10.1182/blood.V130.Suppl_1.3616.3616

Published: 2017

Journal Articles

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura

Blood (2017) 130 (4): 466–471.

https://doi.org/10.1182/blood-2016-12-758656

Published: 2017

Journal Articles

Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes

Blood (2014) 124 (2): 211–219.

https://doi.org/10.1182/blood-2014-02-553131

Published: 2014

Includes: Supplemental data

NARROW

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience

Comparative Effectiveness of Fostamatinib Vs. Rituximab in Refractory Chronic Immune Thrombocytopenia: A Network Meta-Analysis

Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Rationale and Design of an Observational Multicenter Study to Evaluate the Use and Effectiveness of Avatrombopag in Adult Patients with Immune Thrombocytopenia: The Adopt Study

How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

Evans' Syndrome in Adults: An Observational Multicentre Study

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

Outcomes Following Placement of Venous Stents for Treatment of Thrombotic Venous Disease

Characterizing the United Kingdom Congenital Thrombotic Thrombocytopenic Purpura Population

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura

Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only